Moreover, recombinant GM-CSF, marketed as Sargramostim (Sanofi, Paris, France), has been approved for clinical studies, including the treatment of neutropenia in bone marrow transplant recipients, patients undergoing chemotherapy, and carriers of human immunodeficiency virus [51]. Here, CSF2 is linked to neutropenia.